Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | polyketide synthase | 0.095 | 0.4361 | 0.5834 |
Toxoplasma gondii | beta-ketoacyl synthase, N-terminal domain-containing protein | 0.0616 | 0.2149 | 0.2574 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsA | 0.0764 | 0.3131 | 0.4188 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSB | 0.0764 | 0.3131 | 0.4155 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSC | 0.1009 | 0.4752 | 0.6337 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks7 | 0.1009 | 0.4752 | 0.6357 |
Mycobacterium ulcerans | thioesterase | 0.0791 | 0.3311 | 0.443 |
Mycobacterium tuberculosis | Probable thioesterase TesA | 0.0791 | 0.3311 | 0.443 |
Onchocerca volvulus | Fatty acid synthase homolog | 0.1712 | 0.9416 | 1 |
Brugia malayi | Beta-ketoacyl synthase, N-terminal domain containing protein | 0.095 | 0.4361 | 0.4361 |
Mycobacterium tuberculosis | Probable fatty acid synthase Fas (fatty acid synthetase) | 0.0298 | 0.0042 | 0.0056 |
Mycobacterium leprae | PROBABLE THIOESTERASE TESA | 0.0791 | 0.3311 | 0.4398 |
Mycobacterium leprae | Probable polyketide synthase Pks1 | 0.1009 | 0.4752 | 0.6337 |
Loa Loa (eye worm) | hypothetical protein | 0.1595 | 0.8643 | 1 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSA | 0.095 | 0.4361 | 0.581 |
Mycobacterium ulcerans | thioesterase TesA | 0.0791 | 0.3311 | 0.443 |
Mycobacterium tuberculosis | Polyketide synthase Pks13 | 0.1419 | 0.7476 | 1 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsB | 0.0764 | 0.3131 | 0.4188 |
Brugia malayi | AMP-binding enzyme family protein | 0.0887 | 0.3948 | 0.3948 |
Mycobacterium ulcerans | polyketide synthase | 0.1009 | 0.4752 | 0.6357 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks5 | 0.0921 | 0.4168 | 0.5576 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks8 | 0.0777 | 0.3214 | 0.4299 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsD | 0.095 | 0.4361 | 0.5834 |
Mycobacterium tuberculosis | Phenolpthiocerol synthesis type-I polyketide synthase PpsC | 0.095 | 0.4361 | 0.5834 |
Mycobacterium ulcerans | Type I modular polyketide synthase | 0.095 | 0.4361 | 0.5834 |
Mycobacterium tuberculosis | Polyketide synthetase MbtC (polyketide synthase) | 0.0326 | 0.0229 | 0.0306 |
Loa Loa (eye worm) | fatty acid synthase | 0.0937 | 0.4277 | 0.4318 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsE | 0.0628 | 0.2228 | 0.2981 |
Mycobacterium ulcerans | polyketide synthase Pks9 | 0.0628 | 0.2228 | 0.2981 |
Mycobacterium leprae | Probable multifunctional mycocerosic acid synthase membrane associated enzyme Mas | 0.1009 | 0.4752 | 0.6337 |
Mycobacterium tuberculosis | Polyketide synthase Pks2 | 0.0921 | 0.4168 | 0.5576 |
Mycobacterium tuberculosis | Polyketide synthase Pks12 | 0.1009 | 0.4752 | 0.6357 |
Loa Loa (eye worm) | hypothetical protein | 0.0532 | 0.1592 | 0.0823 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsC | 0.1009 | 0.4752 | 0.6357 |
Loa Loa (eye worm) | AMP-binding enzyme family protein | 0.0887 | 0.3948 | 0.3889 |
Mycobacterium tuberculosis | Phenolpthiocerol synthesis type-I polyketide synthase PpsA | 0.095 | 0.4361 | 0.5834 |
Toxoplasma gondii | type I fatty acid synthase, putative | 0.0676 | 0.2547 | 0.3708 |
Mycobacterium ulcerans | Type I modular polyketide synthase | 0.095 | 0.4361 | 0.5834 |
Mycobacterium ulcerans | Type I modular polyketide synthase | 0.095 | 0.4361 | 0.5834 |
Mycobacterium leprae | Polyketide synthase Pks13 | 0.1419 | 0.7476 | 1 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks1 | 0.0682 | 0.2588 | 0.3461 |
Mycobacterium tuberculosis | Phenolpthiocerol synthesis type-I polyketide synthase PpsD | 0.095 | 0.4361 | 0.5834 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSD | 0.095 | 0.4361 | 0.581 |
Mycobacterium tuberculosis | Probable multifunctional mycocerosic acid synthase membrane-associated Mas | 0.1009 | 0.4752 | 0.6357 |
Mycobacterium ulcerans | multifunctional mycocerosic acid synthase membrane-associated Mas | 0.1009 | 0.4752 | 0.6357 |
Onchocerca volvulus | 0.1653 | 0.9025 | 0.9285 | |
Mycobacterium tuberculosis | Probable polyketide synthase Pks9 | 0.054 | 0.1644 | 0.2199 |
Toxoplasma gondii | type I fatty acid synthase, putative | 0.1009 | 0.4752 | 1 |
Mycobacterium tuberculosis | Probable membrane bound polyketide synthase Pks6 | 0.1419 | 0.7476 | 1 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSE | 0.0628 | 0.2228 | 0.2941 |
Mycobacterium ulcerans | polyketide synthase Pks13 | 0.1419 | 0.7476 | 1 |
Mycobacterium tuberculosis | Phenyloxazoline synthase MbtB (phenyloxazoline synthetase) | 0.0887 | 0.3948 | 0.528 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks15 | 0.0384 | 0.061 | 0.0817 |
Mycobacterium ulcerans | fatty acid synthase Fas | 0.0298 | 0.0042 | 0.0056 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 0.54 nM | The compound was tested in vitro for growth of inhibitory activity against lymphoid leukemia L1210 cells | ChEMBL. | 2795608 |
ILS (functional) | = 46 % | Increase in the life span of mice implanted with lymphocytic leukemia P388 at the highest nontoxic dose of 0.5 mg/Kg given to the compound intraperitonialy | ChEMBL. | 2795608 |
MI0.5 (functional) | = 0.74 nM | Mitotic index (fraction of cells in mitosis divided by total cells ) for cultured lymphoid leukemia L1210 cells | ChEMBL. | 2795608 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Mus musculus | ChEMBL23 | 2795608 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.